EXOZYMES INC

Exozymes (EXOZ) faces volatility as CEO reveals AI‑powered cell‑free biomanufacturing plans, targeting nutraceuticals, cannabinoids and new partnerships to boost revenue.

Exozymes drops 2.2% in the last 24 h, trading near its 52‑week low and 34.9% lower than month‑end. Compare its performance to peers like Quetta Acquisition and see what this means for investors.

Exozymes Inc. (EXOZ) shows a potential rebound below its 200‑day SMA, driven by strong board alignment and insider confidence amid biotech volatility.